APC
HAE icon

Aspire Private Capital’s Haemonetics HAE Stock Holding History

Aspire Private Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-75
Closed -$6.72K – 723
2023
Q3 		$6.72K Buy
+75
New +$6.7K ﹤0.01% 445

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aspire Private Capital's HAE Position: Q4 2023 in Review

Aspire Private Capital sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 75 shares — an estimated $6.72K sold.

Aspire Private Capital first reported a position in HAE in Q3 2023 and held it in 1 quarter. The position peaked at $6.72K in Q3 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Aspire Private Capital reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Aspire Private Capital sold 75 Haemonetics shares in Q4 2023, an estimated $6.72K.
  • Aspire Private Capital first reported a position in Haemonetics in Q3 2023 and held it in 1 quarter.
  • Aspire Private Capital's Haemonetics position peaked at $6.72K in Q3 2023.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Aspire Private Capital's 13F filing for Q4 2023, filed 1 Feb 2024.